MX378999B - Fosforamidita de agrupacion de n-acetilgalactosamina (galnac). - Google Patents

Fosforamidita de agrupacion de n-acetilgalactosamina (galnac).

Info

Publication number
MX378999B
MX378999B MX2018005733A MX2018005733A MX378999B MX 378999 B MX378999 B MX 378999B MX 2018005733 A MX2018005733 A MX 2018005733A MX 2018005733 A MX2018005733 A MX 2018005733A MX 378999 B MX378999 B MX 378999B
Authority
MX
Mexico
Prior art keywords
phosphoramidite
galnac
acetylgalactosamine
clustering
sup
Prior art date
Application number
MX2018005733A
Other languages
English (en)
Other versions
MX2018005733A (es
Inventor
RENé TRUSSARDI
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2018005733A publication Critical patent/MX2018005733A/es
Publication of MX378999B publication Critical patent/MX378999B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/08—Polyoxyalkylene derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La invención comprende derivados de fosforamidita de GalNAc de fórmula I (ver Fórmula) en donde R1 es un grupo protector de hidroxi, n es un número entero de 0 a 10 y m es un entero de 0 a 20 y sus enantiómeros correspondientes y/o isómeros ópticos de los mismos. La invención comprende además un proceso para la preparación de los derivados de fosforamidita de GalNAc de fórmula I y su uso en la preparación de conjugados de agrupación de GalNAc -oligonucleótidos terapéuticamente valiosos.
MX2018005733A 2015-11-16 2016-11-14 Fosforamidita de agrupacion de n-acetilgalactosamina (galnac). MX378999B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15194811 2015-11-16
PCT/EP2016/077516 WO2017084987A1 (en) 2015-11-16 2016-11-14 GalNAc CLUSTER PHOSPHORAMIDITE

Publications (2)

Publication Number Publication Date
MX2018005733A MX2018005733A (es) 2018-08-09
MX378999B true MX378999B (es) 2025-03-10

Family

ID=54695483

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018005733A MX378999B (es) 2015-11-16 2016-11-14 Fosforamidita de agrupacion de n-acetilgalactosamina (galnac).

Country Status (14)

Country Link
US (1) US10590156B2 (es)
EP (1) EP3377510B1 (es)
JP (1) JP6649482B2 (es)
KR (1) KR102117172B1 (es)
CN (1) CN108738321B (es)
AR (1) AR106683A1 (es)
AU (1) AU2016357980B2 (es)
BR (1) BR112018003910B1 (es)
CA (1) CA2994787A1 (es)
ES (1) ES2848122T3 (es)
IL (1) IL258149B (es)
MX (1) MX378999B (es)
PL (1) PL3377510T3 (es)
WO (1) WO2017084987A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3013683C (en) 2016-03-14 2021-07-13 F. Hoffmann-La Roche Ag Oligonucleotides for reduction of pd-l1 expression
JP7048574B2 (ja) 2017-03-10 2022-04-05 国立研究開発法人国立成育医療研究センター アンチセンスオリゴヌクレオチドおよび糖原病Ia型予防または治療用組成物
WO2019048632A1 (en) 2017-09-08 2019-03-14 Mina Therapeutics Limited STABILIZED COMPOSITIONS OF SMALL ACTIVATORY RNA (PARNA) OF HNF4A AND METHODS OF USE
SG11202002149XA (en) * 2017-09-14 2020-04-29 Janssen Biopharma Inc Galnac derivatives
WO2019172286A1 (ja) 2018-03-09 2019-09-12 第一三共株式会社 糖原病Ia型治療薬
US11510939B1 (en) 2019-04-19 2022-11-29 Apellis Pharmaceuticals, Inc. RNAs for complement inhibition
CA3134494A1 (en) * 2019-05-20 2020-11-26 Simon Adolf BREITLER Process for the preparation of galnac phosphoramidite epimers
IL291251B2 (en) 2019-09-10 2026-06-01 Daiichi Sankyo Co Limited CONJUGATE OF GalNAC-OLIGONUCLEOTIDE FOR DELIVERY TO LIVER AND MANUFACTURING METHOD THEREOF
CN110668933B (zh) * 2019-09-30 2024-09-24 兰州交通大学 一种合成烯丙基脂肪醇聚氧乙烯醚羧酸(apea-7)的方法
CN110759824B (zh) * 2019-09-30 2024-09-24 兰州交通大学 一种合成烯丙基脂肪醇聚氧乙烯醚羧酸(apea-3)的方法
US12534435B2 (en) 2020-03-27 2026-01-27 Generation Bio Co. Lipids and nanoparticle compositions thereof
CN117642380A (zh) 2021-06-14 2024-03-01 世代生物公司 阳离子脂质及其组合物
EP4471140A1 (en) * 2022-01-30 2024-12-04 Rona Bioscience, Limited Targeting ligand containing n-acetylgalactosamine
IL315659A (en) 2022-03-16 2024-11-01 Daiichi Sankyo Co Ltd siRNA FOR SUPPRESSING EXPRESSION OF TRANSFERRIN RECEPTOR-2
EP4495241A1 (en) 2022-03-16 2025-01-22 Daiichi Sankyo Company, Limited Chemically-modified oligonucleotide having rnai activity
WO2024040222A1 (en) 2022-08-19 2024-02-22 Generation Bio Co. Cleavable closed-ended dna (cedna) and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4420730A3 (en) 2009-03-19 2024-11-13 The Johns Hopkins University Psma-targeting compounds and uses thereof
PH12012501596A1 (en) 2010-02-24 2017-02-03 Arrowhead Res Corporation Compositions for targeted delivery of sirna
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
RU2013117288A (ru) * 2010-12-17 2015-01-27 Эрроухэд Рисерч Корпорейшн СОДЕРЖАЩАЯ ГАЛАКТОЗНЫЙ КЛАСТЕР НАЦЕЛИВАЮЩАЯ ГРУППА ДЛЯ миРНК, МОДУЛИРУЮЩАЯ ФОРМАКОКИНЕТИЧЕСКИЕ СВОЙСТВА
PL2992098T3 (pl) * 2013-05-01 2019-09-30 Ionis Pharmaceuticals, Inc. Kompozycje i sposoby modulowania ekspresji hbv i ttr
MX367083B (es) * 2013-06-27 2019-08-05 Roche Innovation Ct Copenhagen As Oligomeros antisentido y conjugados con diana en la proteina-convertasa subtilisina/kexina tipo 9(pcsk9).
KR20160083876A (ko) 2013-11-14 2016-07-12 로슈 이노베이션 센터 코펜하겐 에이/에스 ApoB 안티센스 접합체 화합물
WO2015168589A2 (en) * 2014-05-01 2015-11-05 Isis Pharmaceuticals, Inc. Compositions and methods for modulating angiopoietin-like 3 expression

Also Published As

Publication number Publication date
JP2018532764A (ja) 2018-11-08
EP3377510B1 (en) 2020-12-02
ES2848122T3 (es) 2021-08-05
US10590156B2 (en) 2020-03-17
BR112018003910A2 (pt) 2018-09-25
KR102117172B1 (ko) 2020-06-01
AU2016357980A1 (en) 2018-02-22
MX2018005733A (es) 2018-08-09
IL258149B (en) 2020-06-30
BR112018003910B1 (pt) 2022-03-22
CA2994787A1 (en) 2017-05-26
AU2016357980B2 (en) 2020-06-25
CN108738321B (zh) 2021-06-11
WO2017084987A1 (en) 2017-05-26
IL258149A (en) 2018-05-31
EP3377510A1 (en) 2018-09-26
CN108738321A9 (zh) 2021-01-29
US20180258122A1 (en) 2018-09-13
AR106683A1 (es) 2018-02-07
CN108738321A (zh) 2018-11-02
PL3377510T3 (pl) 2021-05-04
KR20180041225A (ko) 2018-04-23
JP6649482B2 (ja) 2020-02-19

Similar Documents

Publication Publication Date Title
AR106683A1 (es) FOSFORAMIDITA DE AGRUPACIÓN DE GalNAc
MX380122B (es) Derivado benzofurano, su metodo de preparacion, y sus usos en medicinas.
MA46325A (fr) Composés dinucléotidiques cycliques
BR112018074185A2 (pt) 3-oxo-2,6-difenil-2,3-di-hidropiridazina-4-carboxamidas
MX2017015662A (es) Procesos para la preparacion de derivados acidos de n-acetilgalactosamina (galnac).
MX2020006460A (es) Compuestos de anillo 5,5 fusionado sustituido con diarilo como inhibidores de c5ar.
MX377916B (es) Compuestos 4-amino-imidazoquinolina.
BR112016006151A2 (pt) imidazopiridazinas úteis como inibidores da via de sinalização do par-2
CO6511283A2 (es) Primidinas sustituidas útiles en el tratamiento de enfermedades tales como cancer
BR112018009252A2 (en) osteoarthritis treatment
MX389367B (es) Composiciones farmaceuticas liquidas que comprenden inhibidores de sglt-2.
UY32240A (es) Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones.
MX2021008094A (es) Metodos y composiciones para el tratamiento del cancer.
NZ746906A (en) Oxaborole esters and uses thereof
MX2017003238A (es) Metodo para preparar 2'-o-fucosil-lactosa.
BR112023012947A2 (pt) Inibidores de lrrk2
CO2022009260A2 (es) Composiciones farmacéuticas oftálmicas
MA39337A1 (fr) Modulateurs de pyrazines de gpr6
MX2022006320A (es) Composicion para la inhibicion de la produccion de hmf que comprende disacarido de alulosa.
BR112015015229A8 (pt) processo para a preparação de um composto da fórmula, e, composto
BR112019000290A2 (pt) pró-fármacos de fósforo dos estimuladores da scg
MX2022006003A (es) Glucolipidos y composiciones farmaceuticas de los mismos para usarse en terapia.
MX392144B (es) Compuestos tipo pederina y el uso de los mismos en el tratatamiento de cáncer.
MX2021014111A (es) Proceso para la preparacion de epimeros de fosforamidita de galnac.
MX2020012065A (es) Compuestos de ciclopentano.